{"log_id": 7614165866669612389, "direction": 0, "words_result_num": 38, "words_result": [{"probability": {"variance": 0.104227, "average": 0.677106, "min": 0.354264}, "location": {"width": 50, "top": 67, "height": 28, "left": 1126}, "words": "理"}, {"probability": {"variance": 0, "average": 0.997968, "min": 0.997968}, "location": {"width": 29, "top": 105, "height": 30, "left": 1138}, "words": "件"}, {"probability": {"variance": 0, "average": 0.994902, "min": 0.994902}, "location": {"width": 27, "top": 145, "height": 28, "left": 1129}, "words": "章"}, {"probability": {"variance": 0.000254, "average": 0.994097, "min": 0.90901}, "location": {"width": 764, "top": 198, "height": 37, "left": 223}, "words": "合/躁狂发作加重的可能性。在开始用抗抑郁症药物治疗以前,应当对患者做充分的筛查"}, {"probability": {"variance": 9.3e-05, "average": 0.995083, "min": 0.959831}, "location": {"width": 772, "top": 237, "height": 37, "left": 223}, "words": "确定他们是否有发生双相情感障碍的危险,这种筛查应当包括详细的精神病病史,包括自杀"}, {"probability": {"variance": 0, "average": 0.790355, "min": 0.790355}, "location": {"width": 21, "top": 265, "height": 21, "left": 810}, "words": "t"}, {"probability": {"variance": 0.013746, "average": 0.960629, "min": 0.479535}, "location": {"width": 782, "top": 275, "height": 40, "left": 225}, "words": "双相情感障碍和抑郁症的家族史。应当注意未批准本品用于治疗双相情感障碍。和所有抗抑"}, {"probability": {"variance": 0.001011, "average": 0.992167, "min": 0.846492}, "location": {"width": 435, "top": 321, "height": 35, "left": 227}, "words": "郁药物一样,本品也应当慎用于有躁狂病史的患者"}, {"probability": {"variance": 0.027252, "average": 0.898421, "min": 0.612798}, "location": {"width": 64, "top": 366, "height": 26, "left": 264}, "words": "6.骨折"}, {"probability": {"variance": 5.6e-05, "average": 0.99662, "min": 0.96294}, "location": {"width": 741, "top": 396, "height": 38, "left": 266}, "words": "关于服用抗抑郁药包括 SSRIS有骨折风险的流行病学研究表明其跟骨折有一定的相关"}, {"probability": {"variance": 3.5e-05, "average": 0.996923, "min": 0.966352}, "location": {"width": 783, "top": 436, "height": 38, "left": 225}, "words": "性。该风险发生在治疗过程中并在治疗早期是最大的。骨折被认为有可能发生在服用本品的"}, {"probability": {"variance": 0, "average": 0.999744, "min": 0.999532}, "location": {"width": 62, "top": 488, "height": 23, "left": 228}, "words": "患者中"}, {"probability": {"variance": 0.002975, "average": 0.974771, "min": 0.852837}, "location": {"width": 103, "top": 525, "height": 24, "left": 266}, "words": "7.静坐不能"}, {"probability": {"variance": 0.000105, "average": 0.997155, "min": 0.937213}, "location": {"width": 741, "top": 552, "height": 37, "left": 267}, "words": "罕见的情况下,使用本品或其他 SSRIS可能会出现静坐不能,其特征表现为烦躁不安的"}, {"probability": {"variance": 0.000394, "average": 0.995466, "min": 0.872029}, "location": {"width": 782, "top": 590, "height": 39, "left": 227}, "words": "内心感受和精神运动性兴奋,例如常常由于自觉苦恼,不能静坐或安静站立。这种情况最可"}, {"probability": {"variance": 1e-05, "average": 0.998108, "min": 0.990208}, "location": {"width": 221, "top": 640, "height": 25, "left": 229}, "words": "能发生于治疗的前几周内"}, {"probability": {"variance": 0.006043, "average": 0.980287, "min": 0.624733}, "location": {"width": 403, "top": 672, "height": 35, "left": 266}, "words": "8.5-羟色胺综合征/抗精神病药物恶性综合征"}, {"probability": {"variance": 0.004046, "average": 0.983531, "min": 0.610297}, "location": {"width": 730, "top": 707, "height": 38, "left": 270}, "words": "罕见的情况下,帕罗西汀治疗可能会发生5-羟色胺综合征或抗精神病药物恶性综合征"}, {"probability": {"variance": 0.002597, "average": 0.989314, "min": 0.672845}, "location": {"width": 785, "top": 747, "height": 37, "left": 227}, "words": "特别是与其他拟5羟色胺药物和/或抗精神病药物合用时。因为这些综合征可能导致潜在的"}, {"probability": {"variance": 0.000156, "average": 0.993166, "min": 0.941832}, "location": {"width": 772, "top": 786, "height": 38, "left": 229}, "words": "致命性问题,所以如果发生这些事件(特征表现为多种症状组合,如高热,强直,肌阵挛"}, {"probability": {"variance": 1.6e-05, "average": 0.997898, "min": 0.979861}, "location": {"width": 783, "top": 825, "height": 37, "left": 230}, "words": "自主神经不稳定,可能有生命体征的快速波动,精神状态改变,包括意识模糊、烦躁、极度"}, {"probability": {"variance": 5.5e-05, "average": 0.995537, "min": 0.973649}, "location": {"width": 780, "top": 862, "height": 39, "left": 232}, "words": "兴奋、进展到谵妄和昏迷),应当停用本品,采取支持对症治疗。帕罗西汀不能与拟5羟色"}, {"probability": {"variance": 0.003011, "average": 0.978155, "min": 0.742336}, "location": {"width": 782, "top": 902, "height": 38, "left": 231}, "words": "胺前体物质(如L一色氨酸,羟色胺酸)合用,因为两者合用有发生5-羟色胺综合征的危险"}, {"probability": {"variance": 0.001279, "average": 0.985895, "min": 0.854029}, "location": {"width": 293, "top": 947, "height": 32, "left": 242}, "words": "见【禁忌】和【药物相互作用】)"}, {"probability": {"variance": 5e-06, "average": 0.998293, "min": 0.993921}, "location": {"width": 106, "top": 992, "height": 24, "left": 241}, "words": "【注意事项】"}, {"probability": {"variance": 4.3e-05, "average": 0.996382, "min": 0.966966}, "location": {"width": 735, "top": 1019, "height": 37, "left": 276}, "words": "为了减少用药过量的风险,处方本品时应该选最小剂量的片剂,并与良好的患者管理"}, {"probability": {"variance": 1e-06, "average": 0.9991, "min": 0.997558}, "location": {"width": 103, "top": 1070, "height": 24, "left": 234}, "words": "措施相配套"}, {"probability": {"variance": 0.001149, "average": 0.990629, "min": 0.812659}, "location": {"width": 740, "top": 1096, "height": 36, "left": 272}, "words": "1.筛查双相情感障碍患者:重度抑郁发作可能是双相情感障碍的最初表现,一般认为"}, {"probability": {"variance": 2.9e-05, "average": 0.997392, "min": 0.976442}, "location": {"width": 771, "top": 1134, "height": 38, "left": 243}, "words": "(尽管尚未经对照临床试验所证实),在有双相情感障碍危险的患者中单用抗抑郁药物治疗"}, {"probability": {"variance": 0.000425, "average": 0.993556, "min": 0.891079}, "location": {"width": 774, "top": 1172, "height": 39, "left": 237}, "words": "重度抑郁发作,可能会增加其混合躁狂发作加重的可能性。关于上述的症状是否也会发生"}, {"probability": {"variance": 0.000122, "average": 0.997108, "min": 0.93022}, "location": {"width": 776, "top": 1210, "height": 39, "left": 237}, "words": "这种转变尚不清楚。在开始应用抗抑郁药物治疗以前,应当对患者做充分的筛查,确定他"}, {"probability": {"variance": 0.000757, "average": 0.990833, "min": 0.877105}, "location": {"width": 757, "top": 1250, "height": 38, "left": 237}, "words": "们是否具有发生双相情感障碍的危险:这种筛查应当包括详细的精神病病史,以及自杀"}, {"probability": {"variance": 0.001179, "average": 0.989444, "min": 0.809944}, "location": {"width": 709, "top": 1289, "height": 38, "left": 240}, "words": "双相情感障碍和抑郁症的家族史。应当注意,本品尚未批准用于治疗双相情感障碍"}, {"probability": {"variance": 0.00076, "average": 0.989762, "min": 0.870176}, "location": {"width": 399, "top": 1332, "height": 34, "left": 278}, "words": "2.心脏:心脏病患者应用本品通常应注意观察"}, {"probability": {"variance": 0.00453, "average": 0.976879, "min": 0.667586}, "location": {"width": 469, "top": 1371, "height": 34, "left": 279}, "words": "3.癫痫发作:与其它精神科药物一样,癫痫患者慎用"}, {"probability": {"variance": 0.001532, "average": 0.986573, "min": 0.818651}, "location": {"width": 720, "top": 1406, "height": 38, "left": 281}, "words": "总的来说,使用本品治疗过程中癫痫发作的发病率<0.1%癫痫发作的患者应停止用药"}, {"probability": {"variance": 0.002949, "average": 0.972112, "min": 0.86351}, "location": {"width": 83, "top": 1456, "height": 24, "left": 280}, "words": "4.青光眼"}, {"probability": {"variance": 0.008801, "average": 0.969979, "min": 0.556396}, "location": {"width": 739, "top": 1483, "height": 38, "left": 283}, "words": "与其它选择性51T再摄取抑制剂( SSRIS)相比,本品可能会引起瞳孔扩大,房角变窄的"}], "language": 3}